In this episode, Dr. Stefan Zeuzem discusses results from key viral hepatitis studies reported at the 2020 Digital International Liver Congress, organized by the European Association for the Study of the Liver, including important findings from the following reports:Update on global progress toward HCV elimination goalsSToP-C: HCV treatment-as-prevention in Australian prisonsSHARED cohort: correlates of treatment failure with GLE/PIB or SOF/VEL/VOXTrio Health: retreating HCV with GLE/PIB or SOF/VEL/VOX after DAA failureStop-NUC: discontinuation of long-term nucleos(t)ide analogue therapy in patients with HBeAg-negative chronic HBV infectionHigh-dose bulevirtide for chronic HBV/HDV coinfectionSummary of select agents under early-phase investigation for HBV treatmentPresenter:Stefan Zeuzem, MDProfessor of Medicine Chief, Department of Medicine I JW Goethe University Hospital Frankfurt, GermanyContent based on a CME program supported by an independent educational grant from Gilead Sciences.Link to full program:https://bit.ly/33nkRUI Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related